EGFR mutant NSCLC is characterized by a pathology wherein unlike the de novo T790M, the T790M prevails via exon 19 deletions than in L858R mutated EGFR-TKI resistant sufferers [24]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.